The Lancet

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

lCentre for Immunobiology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK ...